Podcasts about urticaria

Summary In this truncated replay, Dr. Shyam Joshi explores the intersection between allergy and dermatology—focusing on how chronic spontaneous urticaria (CSU), atopic dermatitis, and food allergies often overlap. Learn how emerging biologics like omalizumab and dupilumab are reshaping treatment decisions, why comorbidities matter, and how collaboration between allergists and dermatologists creates better outcomes for patients with complex allergic and dermatologic conditions. This episode dives into real-world case studies, FDA updates on antihistamines, and the multidisciplinary approach to managing eczema and CSU in pediatric and adult populations. Takeaways - FDA Advisory on Antihistamines: Long-term use of cetirizine or levocetirizine can lead to rebound pruritus upon discontinuation—but gradual tapering minimizes symptoms. - Biologic Selection Depends on Comorbidities: - Omalizumab is effective for IgE-mediated food allergies and chronic urticaria. - Dupilumab is preferred for patients with eosinophilic esophagitis (EoE) or moderate-to-severe atopic dermatitis. - CSU Is Systemic: Symptoms may extend beyond hives—impacting joints, sleep, and energy levels. - Comorbid Conditions Are Common: Up to 20 % of CSU patients have asthma, allergic rhinitis, or food allergies; identifying these helps guide treatment and patient education. - Unified Messaging Builds Trust: Consistent communication from both dermatologists and allergists reduces unnecessary testing and supports adherence to treatment plans. Chapters 00:00 - Introduction: Bridging Allergy and Dermatology 00:45 - Case Study: An 18-Year-Old with Chronic Urticaria 02:00 - FDA Warning: Antihistamine Withdrawal Itch 03:45 - Selecting the Right Biologic: Food Allergy Considerations 04:45 - Eosinophilic Esophagitis and CSU         05:35 - The Systemic Nature of CSU 06:40 - Comorbidities in CSU and Atopic Patients 07:30 - Multidisciplinary Collaboration in Practice 08:00 - Closing Thoughts & Educational Disclaimer

Summary In this truncated replay, Dr. Jason Hawkes discusses the complexities of urticaria, a skin condition often overlooked in dermatology. He highlights the importance of understanding urticaria's symptoms, diagnosis, and management, particularly in chronic cases. The conversation also touches on the relationship between urticaria and autoimmune diseases, the necessity of testing, and the overall approach to treatment. Takeaways - Dermatology has historically overlooked urticaria management. - Urticaria is characterized by transient lesions lasting hours. - Chronic urticaria can persist for years without clear triggers. - Women are more likely to experience chronic urticaria due to autoimmune factors. - Extensive testing for urticaria is often unnecessary and unhelpful. - Understanding the nature of angioedema is crucial in diagnosis. - Patients may experience both hives and angioedema simultaneously. - Management strategies should focus on improving patient quality of life. - Autoimmunity plays a significant role in urticaria cases. - Education and awareness are key in dermatology practices regarding urticaria. Chapters 00:00 - Introduction to Urticaria in Dermatology 02:44 - Understanding Urticaria: Symptoms and Diagnosis 06:03 - Chronic Urticaria: Nature and Management 08:58 - Autoimmunity and Urticaria: Exploring Connections 11:48 - Testing and Treatment Approaches for Urticaria

Hoy, 1 de octubre, Día Mundial de la Urticaria, nos sumergimos en una enfermedad que muchos piensan que es “solo un sarpullido”, pero que puede cambiar la vida de quien la padece. La urticaria no solo pica: afecta al sueño, al trabajo, a las relaciones sociales… e incluso a la salud mental.Para entenderla mejor charlamos con dos especialistas:

Is that penicillin or amoxicillin allergy real? Probably not. In this episode, we explore how to assess risk, talk to parents, and refer for delabeling. You'll also learn what happens in the allergy clinic, why the label matters, and how to be a better antimicrobial steward. Learning Objectives Describe the mechanisms and clinical manifestations of immediate and delayed hypersensitivity reactions to penicillin, including diagnostic criteria and risk stratification tools such as the PEN-FAST score. Differentiate between low-, moderate-, and high-risk penicillin allergy histories in pediatric patients and identify appropriate candidates for direct oral challenge or allergy referral based on current evidence and guidelines. Formulate an evidence-based approach for evaluating and counseling families in the Emergency Department about reported penicillin allergies, including when to recommend outpatient referral for formal delabeling. Connect with Brad Sobolewski PEMBlog: PEMBlog.com Blue Sky: @bradsobo X (Twitter): @PEMTweets Instagram: Brad Sobolewski References Khan DA, Banerji A, Blumenthal KG, et al. Drug Allergy: A 2022 Practice Parameter Update. J Allergy Clin Immunol. 2022;150(6):1333-1393. doi:10.1016/j.jaci.2022.08.028 Moral L, Toral T, Muñoz C, et al. Direct Oral Challenge for Immediate and Non-Immediate Beta-Lactam Allergy in Children. Pediatr Allergy Immunol. 2024;35(3):e14096. doi:10.1111/pai.14096 Castells M, Khan DA, Phillips EJ. Penicillin Allergy. N Engl J Med. 2019;381(24):2338-2351. doi:10.1056/NEJMra1807761 Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and Management of Penicillin Allergy: A Review.JAMA. 2019;321(2):188–199. doi:10.1001/jama.2018.19283 Transcript Note: This transcript was partially completed with the use of the Descript AI and the Chat GPT 5 AI  Welcome to PEM Currents, the Pediatric Emergency Medicine podcast. As always, I'm your host, Brad Sobolewski, and today we are taking on a label that's misleading, persistent. Far too common penicillin allergy, it's often based on incomplete or inaccurate information, and it may end up limiting safe and effective treatment, especially for the kids that we see in the emergency department. I think you've all seen a patient where you're like. I don't think this kid's really allergic to amoxicillin, but what do you do about it? In this episode, we're gonna break down the evidence, walk through what actually happens during de labeling and dedicated allergy clinics. Highlight some validated tools like the pen FAST score, which I'd never heard of before. Preparing for this episode and discuss the current and future role of ED based penicillin allergy testing. Okay, so about 10% of patients carry a penicillin allergy label, but more than 90% are not truly allergic. And this label can be really problematic in kids. It limits first line treatment choices like amoxicillin, otitis media, or penicillin for strep throat, and instead. Kids get prescribed second line agents that are less effective, broader spectrum, maybe more toxic or poorly tolerated and associated with a higher risk of antimicrobial resistance. So it's not just an EMR checkbox, it's a label with some real clinical consequences. And it's one, we have a role in removing. And so let's understand what allergy really means. And most patients with a reported penicillin allergy, especially kids, aren't true allergies in the immunologic sense. Common misinterpretations include a delayed rash, a maculopapular, or viral exum, or benign, delayed hypersensitivity, side effects, nausea, vomiting, and diarrhea. And unverified childhood reactions that are undocumented and nonspecific. Most of these are not true allergies. Only a very small subset of patients actually have IgE mediated hypersensitivity, such as urticaria, angioedema, wheezing, and anaphylaxis. These are super rare, and even then they may resolve over time without treatment. If a parent or sibling has a history of a penicillin allergy, remember that patient might actually not be allergic, and that is certainly not a reason to label a child as allergic just because one of their first degree relatives has an allergy. So right now, in 2025, as I'm recording this episode, there are clinics like the Pats Clinic or the Penicillin Allergy Testing Services at Cincinnati Children's and in a lot of our peer institutions that are at the forefront of modern de labeling. Their approach reflects the standard of care as outlined by the. Quad ai or the American Academy of Allergy, asthma and Immunology and supported by large trials like Palace. And you know, you have a great trial if you have a great acronym. So here's what happens step by step. So first you stratify the risk. How likely is this to be a true allergy? And that's where a tool like the pen fast comes. And so pen fast scores, a decision rule developed to help assess the likelihood of a true penicillin allergy based on the patient's history. The pen in pen fast is whether or not the patient has a self-reported history of penicillin allergy. They get two points if the reaction occurred in the past five years. Two points if the reaction is anaphylaxis or angioedema. One point if the reaction required treatment, and one point if the reaction was not due to testing. And so you can get a total score of. Up to six points. If you have a score of less than three. This is a low risk patient and they can be eligible for direct oral challenge. A score greater than three means they're higher risk and they may require skin testing. First validation studies show that the PEN FFA score of less than three had a negative predictive value of 96.3%. Meaning a very, very low chance of a true allergy. And this tool has been studied more extensively in adults, but pediatric specific adaptations are emerging, and they do inform current allergy clinic protocols. But I would not use this score in the emergency department just to give a kid a dose of amoxicillin. So. For low risk patients, a pen fast score of less than three or equivalent clinical judgment clinics proceed with direct oral challenge with no skin testing required. The protocol is they administer one dose of oral amoxicillin and they observe for 62 120 minutes monitoring for signs of reaction Urticaria. Respiratory symptoms or GI upset. This approach is safe and effective. There was a trial called Palace back in 2022, which validated this in over 300 children. In adolescents. There were no serious events that occurred. De labeling was successful in greater than 95% of patients. And skin tested added no benefit in low risk patients. So if the child tolerates this dose, then you can remove that allergy immediately from the chart. Parents and primary care doctors will receive a summary letter noting that the challenge was successful and that there's new guidance. Children and families are told they can safely receive all penicillins going forward. And providers are encouraged to document this clearly in the allergy section of the EMR. So you're wondering, can we actually do this in the emergency department? Technically, yes, you can do what you want, but practically we're not quite there yet. So we'd need clearer risk stratification tools like the Pen fast, a safe place for monitoring, post challenge, clinical pathways and documentation support. You know, a clear way to update EMR allergy labels across the board and involvement or allergy or infectious disease oversight. But it's pretty enticing, right? See a kid you diagnose otitis media. You think that their penicillin allergy is wrong, you just give 'em a dose of amox and watch 'em for an hour. That seems like a pretty cool thing that we might be able to do. So some centers, especially in Canada and Australia, do have some protocols for ED or inpatient based de labeling, but they rely on that structured implementation. So until then, our role in the pediatric emergency department is to identify low risk patients, avoid over document. Unconfirmed reactions and refer to allergy ideally to a clinic like the pets. So who should be referred and good candidates Include a child with a rash only, especially one that's remote over a year ago. Isolated GI symptoms. Parents unsure of the details at all. No history of anaphylaxis wheezing her hives, and no recent serious cutaneous reactions. I would avoid referring and presume that this allergy is true. If they've had recent anaphylaxis, they've had something like Stevens Johnson syndrome dress, or toxic epidermolysis necrosis. Fortunately, those are very, very rare with penicillins and there's a need for penicillin during the ED visit without allergy backup. So even though we don't have an ED based protocol yet. De labeling amoxicillin or penicillin allergy can start with good questions in the emergency department. So here's one way to talk to patients and families. You can say, thanks for letting me know about the amoxicillin allergy. Can I ask you a few questions to better understand what happened? This is gonna help us decide the safest and most effective treatment for your child today, and then possibly go through a process to remove a label for this allergy that might not be accurate. You wanna ask good, open-ended questions. What exactly happened when your child took penicillin or amoxicillin? You know, look for rash, hives, swelling, trouble breathing, or anaphylaxis. Many families just say, allergic, when the reaction was just GI upset, diarrhea or vomiting, which is not an allergy. How old was your child when this happened? Reactions that occurred before age of three are more likely to be falsely attributed. How soon after taking the medicine did the reaction start? Less than one hour is an immediate reaction, but one hour to days later is delayed. Usually mild and probably not a true allergy. Did they have a fever, cold or virus at that time? Viral rashes are often misattributed to antibiotics, and we shouldn't be treating viruses with antibiotics anyway, so get good at looking at ears and know what you're seeing. And have they taken similar antibiotics since then? Like. Different penicillins, Augmentin, or cephalexin. So if they said that they were allergic to amoxicillin, but then somehow tolerated Augmentin. They're not allergic. If a patient had rash only, but no hive swelling or difficulty breathing, no reaction within the first hour. It occurred more than five years ago or before the kid was three. And especially if they tolerated beta-lactam antibiotics. Since then, they're a great candidate for de labeling and I would refer that kid to the allergy clinic. Generally, they can get them in pretty darn quick. Alright, we're gonna wrap up this episode. Most kids labeled penicillin allergic or amoxicillin allergic, or not actually allergic to the medication. There are some scores like pen fasts that are validated tools to assess risk and support de labeling. Direct oral challenge for most patients is safe, efficient, and increasingly the standard of care. There are allergy clinics like the Pats at Cincinnati Children's that can dela children in a single visit with oral challenges alone, needing no skin testing, and emergency departments can play a key role in identifying and referring these patients and possibly de labeling ourselves in the future. Well, that's all for this episode on Penicillin Allergy. I hope you learn something new, especially how to assess whether an allergy label is real, how to ask the right questions and when to refer to an allergy testing clinic. If you have feedback, send it my way. Email, comment on the blog, a message on social media. I always appreciate hearing from you all, and if you like this episode, please leave a review on your favorite podcast app. Really helps more people find the show and that's great 'cause I like to teach people stuff. Thanks for listening for PEM Currents, the Pediatric Emergency Medicine podcast. This has been Brad Sobolewski. See you next time.

When people get hives or swelling, they often think it's caused by an allergy. But in the case of chronic spontaneous urticaria (CSU), the culprit is often your own immune system. CSU isn't your typical allergic reaction, instead, it's frequently an autoimmune condition, where the immune system misfires and activates mast cells without any external trigger. In this episode, Dr. Payel Gupta and Kortney unpack what it means for CSU to be autoimmune and autoallergic. They explain how IgE and IgG antibodies can trigger histamine release, leading to hives and swelling. You'll also learn why allergy testing isn't useful for diagnosing CSU, and how tests like IgG food sensitivity panels can do more harm than good by leading to unnecessary food avoidance and confusion. What we cover in our episode about autoimmune CSU and chronic hives: Is CSU an allergy? Why CSU is often mistaken for an allergic reaction—and why standard allergy tests rarely provide helpful answers. How the immune system works in CSU: What mast cells are, how they release histamine, and their central role in chronic spontaneous urticaria. Understanding autoimmune CSU: Learn how the immune system can trigger hives from within, including the roles of IgE and IgG antibodies. Autoimmune hives explained: We explore how CSU can be autoimmune, why the immune system may attack itself, and what Type I and Type IIb autoimmune CSU really mean. ____ Made in partnership with The Allergy & Asthma Network. Thanks to Novartis for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Definitions and distinguishing features of urticaria and angioedema Common causes of acute urticaria in children and why infection is the leading driver When to suspect IgE-mediated allergy and how to recognise signs of anaphylaxis Practical dosing guidance for non-sedating antihistamines and the role of steroids Red flags that warrant referral and the place of biologics in chronic urticaria Host: Dr Rebecca Overton, GP and Medical Educator Expert: Dr Gabby Mahoney, Paediatric Allergist and Immunologist Total time: 35 mins Register for our fortnightly FREE WEBCASTS Every second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.

Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment

Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment

Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment

Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment

In this episode, we review the high-yield topic ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Urticaria ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Dermatology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

In this episode, Daisy and Olivia eulogise some of the Us in the history of medicine: ugliness, urticaria and universal medicines. _______________ Follow us on: Bluesky - @physiciansgallery Instagram - @physiciansgallery TikTok - @physiciansgallery Facebook - www.facebook.com/PhysiciansGallery Sign up for our newsletter - www.rcpe.ac.uk/newsletter To support heritage at the RCPE, please donate: www.rcpe.ac.uk/donate _______________ The Team: Olivia Howarth (@oh_archives) - Researcher/Presenter Dr Charlotte Holmes (@_CCHolmes_) - Researcher/Presenter Dr Daisy Cunynghame (@RCPEHeritage) - Researcher/Presenter Laura Burgess (@laura.burgess.18) - Producer/Social Media/Presenter Dr Sarah Hayward - Editor/Producer

In this episode, Daisy and Olivia eulogise some of the Us in the history of medicine: ugliness, urticaria and universal medicines. _______________ Follow us on: Bluesky - @physiciansgallery Instagram - @physiciansgallery TikTok - @physiciansgallery Facebook - www.facebook.com/PhysiciansGallery Sign up for our newsletter - www.rcpe.ac.uk/newsletter To support heritage at the RCPE, please donate: www.rcpe.ac.uk/donate _______________ The Team: Olivia Howarth (@oh_archives) - Researcher/Presenter Dr Charlotte Holmes (@_CCHolmes_) - Researcher/Presenter Dr Daisy Cunynghame (@RCPEHeritage) - Researcher/Presenter Laura Burgess (@laura.burgess.18) - Producer/Social Media/Presenter Dr Sarah Hayward - Editor/Producer

Summary In this truncated replay from a session at the 2025 SF Derm Annual Conference, Dr. Daniel Butler, Dr. Lawrence Eichenfield, Dr. Jason Hawkes, Dr. Shyam Joshi, and Dr. Bob Geng discuss the workup for chronic urticaria, focusing on testing approaches, the role of biomarkers, and insights into immune deficiencies. These panelists share their experiences and guidelines, emphasizing the importance of symptomatic management and the variability of lab results in clinical practice. Takeaways - Initial workup for chronic urticaria often does not require specific testing. - Testing may be justified if standard treatments fail. - International guidelines differ from US guidelines regarding testing. - Biomarkers currently available are not reliable for treatment decisions. - Symptomatic management should be prioritized over extensive testing. - Clinical trials show variability in lab results over time. - Excessive lab testing can lead to confusion and unnecessary anxiety for patients. - Understanding patient history is crucial in diagnosing immune deficiencies. - The role of family history is significant in identifying X-linked conditions. - Collaboration among dermatologists is essential for advancing treatment approaches. Chapters 00:00 - Introduction to Chronic Urticaria Workup 02:47 - Testing Approaches and Guidelines for Chronic Urticaria 05:41 - The Role of Biomarkers in Treatment Decisions 08:16 - Clinical Insights on Immune Deficiencies 11:14 - Variability in Lab Results and Clinical Trials 14:07 - Conclusion and Future Directions in Dermatology

Do adults with chronic spontaneous urticaria (CSU) have a higher risk of death over time compared to people without hives? We review the findings from “Mortality in adult patients with chronic spontaneous urticaria: A real-world cohort study,” published in April 2025, in The Journal of Allergy and Clinical Immunology. While CSU is often considered a non-life-threatening condition, this large study found something surprising: people with CSU had a significantly higher risk of death, especially from suicide. Dr. G and Dr. Blaiss walk through key takeaways from a dataset of over 272,000 CSU patients and nearly 13 million matched controls. They explore what the results mean for mortality risk, clinical care, mental health screening, and the importance of proper, guideline-based treatment. What we cover in our episode about CSU and mortality risk: What is CSU? Chronic hives are an unpredictable, itchy, and sometimes painful condition. It lasts for 6 weeks or longer and can continue for years. Mental health connection: CSU affects more than skin. Anxiety, depression, and suicidal thoughts are common and serious concerns. Study findings: CSU was associated with higher mortality at 3 months, 1 year, and 5 years. Suicide risk was over 3 times higher than in people without CSU. Demographics: Younger and White patients with CSU had the highest increase in risk. Treatment impact: Patients using guideline-recommended treatments like second-generation antihistamines or omalizumab had lower death rates. INFOGRAPHIC The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference.   Made in partnership with The Allergy & Asthma Network. Thanks to Novartis for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Carlos León, nuestro Alergólogo de cabecera nos explica ¿por qué nos da urticaria?, ¿son solo ronchas?, ¿cuándo debemos correr con el doctor?, ¿se puede complicar? y todo lo que tienen que saber.  Hosted on Acast. See acast.com/privacy for more information.

Dr. Feldman on NEGATIVITY BIAS -Curettage alone for NMSC - with Dr. Nathan Jensen! -Dupilumab for chronic spontaneous urticaria -ILK for KAs -Learn more about the U of U Dermatology ECHO model!https://physicians.utah.edu/echo/dermatology-primarycareWant to donate to the cause? Do so here!
Donate to the podcast: ⁠uofuhealth.org/dermasphere⁠
Check out our video content on YouTube:
⁠www.youtube.com/@dermaspherepodcast⁠
and VuMedi!: ⁠www.vumedi.com/channel/dermasphere/⁠
The University of Utah's Dermatology
ECHO: ⁠⁠physicians.utah.edu/echo/dermatology-primarycare⁠ -
⁠ Connect with us!
- Web: ⁠⁠dermaspherepodcast.com/⁠⁠ - Twitter: @⁠DermaspherePC⁠
- Instagram: dermaspherepodcast
- Facebook: ⁠www.facebook.com/DermaspherePodcast/⁠
- Check out Luke and Michelle's other podcast,
SkinCast! ⁠⁠healthcare.utah.edu/dermatology/skincast/⁠⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our
friends at:
- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)
- ⁠⁠www.levelex.com/games/top-derm⁠⁠ (A free dermatology game to learn
more dermatology!

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/answers-in-chronic-spontaneous-urticaria-10190SummaryIn this short CE/CME activity, moderator Dr. Brad Glick works with dermatology expert Dr. Gil Yosipovitch to answer your top questions regarding chronic spontaneous urticaria, as gathered from the 2025 NACE Conversations in Dermatology symposium. Questions cover diagnosis, treatment individualization, and more!Learning ObjectivesAt the conclusion of this activity, participants should be better able to:Assess the disease burden and impact on QoL in patients with CSUEvaluate current and emerging therapies for CSUThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis activity is supported by an independent educational grant from Sanofi and Regeneron Pharmaceuticals.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QPE865. CME/MOC/AAPA credit will be available until June 20, 2026.Advancing Care for Chronic Spontaneous Urticaria: Navigating an Evolving Treatment Landscape for Optimal Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QPE865. CME/MOC/AAPA credit will be available until June 20, 2026.Advancing Care for Chronic Spontaneous Urticaria: Navigating an Evolving Treatment Landscape for Optimal Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DNY865. CME credit will be available until June 11, 2026.From Wheals to Wellness: Transforming Chronic Spontaneous Urticaria Care With Emerging SolutionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DNY865. CME credit will be available until June 11, 2026.From Wheals to Wellness: Transforming Chronic Spontaneous Urticaria Care With Emerging SolutionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DNY865. CME credit will be available until June 11, 2026.From Wheals to Wellness: Transforming Chronic Spontaneous Urticaria Care With Emerging SolutionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DNY865. CME credit will be available until June 11, 2026.From Wheals to Wellness: Transforming Chronic Spontaneous Urticaria Care With Emerging SolutionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DNY865. CME credit will be available until June 11, 2026.From Wheals to Wellness: Transforming Chronic Spontaneous Urticaria Care With Emerging SolutionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DNY865. CME credit will be available until June 11, 2026.From Wheals to Wellness: Transforming Chronic Spontaneous Urticaria Care With Emerging SolutionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DNY865. CME credit will be available until June 11, 2026.From Wheals to Wellness: Transforming Chronic Spontaneous Urticaria Care With Emerging SolutionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

Episode Highlights With DaniHer 24 years spent with chronic lifestyle diseases like IBS, Lupus, urticaria, and othersShe was 24 years in before a doctor asked what she was eating If you were born healthy… you do not have to live sick!How quickly the body can adapt when given the right inputsHealing is incredibly simple, but not easyShe starts with diet first and then builds from there… the importance of single-ingredient foodsReal food goes bad… auditing your food choices, and cooking is self-careThe top seven most inflammatory foods in the modern diet and why she does food sensitivity testImportance of sleep and how if we don't sleep, we don't healBallroom dancing is the number one way to decrease Alzheimer's and dementia riskHow data shows that community is extremely important to healthWe are a nation of empty vessels Rest and self-care are so important, and we often forget these- you cannot serve from an empty vesselResources MentionedDani Williamson - WebsiteWild & Well: Dani's Six Commonsense Steps to Radical Healing by Dani Williamson

Klinisch Relevant ist Dein Wissenspartner für das Gesundheitswesen. Drei mal pro Woche, nämlich dienstags, donnerstags und samstags, versorgen wir Dich mit unserem Podcast und liefern Dir Fachwissen für Deine klinische Praxis. Weitere Infos findest Du unter https://klinisch-relevant.de

Adam Friedman, MD, FAAD interviewed by Sabrina Shearer, MD, FAAD

Summary In this episode of the Future of Dermatology Podcast, we revisit the 2024 SF Derm Society's Annual Conference where Dr. Jason Hawkes discusses the complexities of urticaria, including its definitions, types, and the role of mast cells in the condition. This presentation highlights the differences between acute and chronic urticaria, the importance of understanding autoimmunity in relation to urticaria, and the latest treatment approaches, including innovative therapies like Omalizumab. The episode concludes with a call to action for dermatologists to embrace the treatment of urticaria and engage with their patients effectively. Takeaways - Urticaria is often misunderstood, but it has exciting aspects to explore. - Acute urticaria lasts less than six weeks, while chronic urticaria lasts longer. - Chronic spontaneous urticaria (CSU) is often idiopathic and can last for years. - Mast cells play a central role in the pathophysiology of urticaria. - Autoimmunity is a common theme in patients with urticaria, especially in women. - Diagnosis of urticaria is primarily clinical, with no specific lab tests required. - Many patients do not respond to standard antihistamine treatments. - Omalizumab is a powerful treatment option for chronic urticaria. - Anaphylaxis is rare in patients treated with Omalizumab for urticaria. - Dermatologists should feel confident in treating urticaria with available therapies. Chapters 00:00 - Introduction to the Future of Dermatology Podcast 00:57 - Understanding Urticaria: Definitions and Types 03:50 - Differentiating Acute and Chronic Urticaria 06:13 - The Role of Mast Cells in Urticaria 09:03 - Autoimmunity and Urticaria: Comorbidities and Testing 10:59 - Diagnosis and Treatment Approaches for Urticaria 13:52 - Innovative Therapies: Omalizumab and Beyond 15:42 - Conclusion and Call to Action

Hola :) En el episodio de hoy os voy a hablar de todo lo relacionado con la amina biogena que produce nuestro cuerpo de manera normal y qué cuando esta en equilibrio es clave para el sistema inmune, la memoria, el manejo del dolor, la producción de acido estomacal y el control del apetito PERO que cuándo está en exceso, puede darnos lugar a sintomas y signos tan "poco" relacionados entre sí como:Urticaria, picor de la pielDistensión abdominal, dolor abdominal, diarreasMoqueo nasal, picor nasal, tos, lagrimeo continuoHipotensión taquicardiaDolor muscular y articularAdemas os contatré cuales pueden ser los origenes endogenos (nuestro cuerpo) y exogenos (la dieta o fármacos) de la acumulación de histaminaQué podemos hacer para diagnosticar el exceso de histamina, descartando antes la mastocitosis, el sindrome de activación mastocitaria, enfermedades como enfermedad celiaca, situaciones autoinmunes ...Qué alimentos son altos en histamina, cuales son bajosSuplementos que pueden ayudar: quercetina, vitamina D, butirato, trans resveratrol, probioticos como L. rhamnosus GG, L. plantarum...Para mas información ya sabéis que me tenéis en mi instagram @isabelvina dónde te comparto contenido diario Mi TikTok @isabelvinabas En mi canal de YouTube https://www.youtube.com/channel/UC-dfdxLBcvfztBvRAKZSXGQ Y los suplementos formulados por mi https://ivbwellness.com

In this episode of The Health Fix Podcast, Dr. Jannine Krause sits down with Nicole Bonneville, a video media and marketing expert and cohost of the Homance Chronicles on Women in History. Nicole is dedicated to spreading awareness of chronic health and autoimmune conditions to help others find answers faster. Nicole shares her journey—from being stopped at border patrol for being radioactive in her teens to navigating chronic Urticaria, GERD, and the frustrating runaround from the medical system. She opens up about the emotional toll, financial strain, and repeated dead ends, while also providing practical self-advocacy tips for those facing similar struggles. What You'll Learn In This Episode: Why hives often stem from internal, not external, sources The connection between gut health, histamine, and autoimmune conditions How to advocate for yourself when doctors don't have answers What to say when your doctor refuses to run more tests The power of having a program to track symptoms Why condition-focused groups provide more value than Google searches The importance of trusting your intuition on your health journey Resources From The Show:

Urticaria is a skin reaction that causes itchy welts. Chronic hives are welts that last for more than six weeks and return often over months or years. What causes it and what the treatment? To discuss further Pat spoke to Selene Daly Tarpey, Nurse Tutor and Registered Advanced Nurse Practitioner.

With a range of treatments available to treat moderate to severe psoriasis, it can be tough to navigate the landscape. Kara Gooding, MMS, PA-C and Joe Gorelick, MSN, FNP-C provide updates on pathogenesis and the latest treatments. Plus, Jayme Heim, MSN, FNP-BC addresses the diagnosis of CSU and Ted Rosen, MD talks about the challenges of diagnosing STIs. Like what you're hearing? Want to learn more about the Dermatology Education Foundation? Explore assets and resources on our website.

Episode 103 – What steps can be taken to manage solar urticaria? Professor Torsten Zuberbier and Dr Lea Kiefer examine solar urticaria, discussing the role of skin type, management strategies, and treatment methods.

Episode 102 – Professor Torsten Zuberbier welcomes Dr Luis Ensina to discuss essential information for people with urticaria, highlighting the benefits of keeping a diary before medical appointments and how using patient-reported outcome tools can help doctors understand their condition better.

Episode 101 – What were the highlights at Global Urticaria Forum (GUF) 2024? Professor Torsten Zuberbier and Dr Sophia Neisinger share their live reflections on the 7th Global Allergy and Asthma Excellence Network GUF event, including personal highlights, tips for junior physicians to make meaningful contributions to meetings and details on GUF 2025. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria' podcast episodes! For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.

Aimar Bretos, sobre la ausencia de PP y VOX en el acto de mañana por la muerte de Franco

Episode 100 – In this special episode, recorded on Urticaria Day (UDAY), Professor Torsten Zuberbier and Dr Carolina Vera welcome CSU patient advocate Kristen Willard, who shares her story of living with urticaria. With live audience participation, this episode also delves into the cause of itch, the impact of urticaria on mental health, and novel treatments. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria' podcast episodes! For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry. 

Discover Meka's journey with chronic hives in skin of color—a powerful story of resilience, self-advocacy, and building the right support system to get the care she deserves. Emmeka, or "Meka," joins Dr. Gupta and Kortney to share her personal experience of living with chronic urticaria as a person with skin of color. Meka describes her journey from a lack of resources addressing hives on black skin to finding effective support and resources. She opens up about the long path to her diagnosis, the depth of her online research into chronic spontaneous urticaria (CSU), and the importance of finding knowledgeable, empathetic healthcare providers. Meka's optimism highlights how a proactive approach, a trusted care team, and a strong support network can make a difference in managing CSU. What we cover in our episode about living with hives in black skin: Identifying Hives on Darker Skin: Meka shares the challenge of finding accurate images of hives on darker skin tones, which can complicate the first steps of recognizing your condition and create feelings of isolation. Advocating for Yourself in Healthcare: Meka provides strategies for effective self-advocacy during the diagnosis process, including tips for clear communication with healthcare providers. Building a Support Network: Meka emphasizes the value of connecting with others who share similar experiences, including support groups and online communities. Managing Symptoms & Minimizing Scars: Meka offers practical advice for managing CSU symptoms, reducing scarring, and strategies to avoid scratching.

Chronic hives (urticaria) don't look the same on everyone, and for people with skin of color, this can lead to confusion, misdiagnosis, and frustrating delays in treatment. Dr. Ama Alexis joins Dr. Gupta and Kortney to discuss the unique challenges of diagnosing and managing urticaria in skin of color. Chronic spontaneous urticaria (CSU) can be especially tricky to identify in patients with darker skin tones, where traditional medical resources and visual aids often fall short. Dr. Alexis explains how CSU appears differently in skin of color, discussing the difficulty of capturing hives on black and brown skin and offering advice for photographing hives to share with your doctor. Dr. Gupta and Dr. Alexis also delve into the lack of diversity in clinical research and medical literature, exploring how these gaps contribute to mistrust and delays in treatment for patients of color. We end with a discussion on whether patients have better outcomes with providers who reflect the patient's background. What we cover in our episode about chronic urticaria in skin of color: Identifying CSU in Darker Skin Tones: Dr. Alexis shares insights on how hives appear on darker skin and gives tips for photographing hives accurately. Limited Visual Resources for Skin of Color: We discuss how a lack of reliable images for darker skin often leads to confusion and feelings of isolation. Provider Training and Diagnosis Delays: Dr. Alexis highlights how limited training in diagnosing skin conditions across all skin tones contributes to delays in care. Collaborating on a Treatment Plan: Tips for patients on advocating for inclusive care, with guidance on both over-the-counter and prescription options. Cultural Sensitivity in Healthcare: Dr. Alexis shares ways healthcare providers can foster shared decision-making to improve outcomes for patients of color. More resources about chronic hives in skin of color:  Chronic Urticaria Management, Resources & Glossary of Terms What is Chronic Urticaria Chronic Hives: 10 Actions to Support Mental Health Chronic Spontaneous Urticaria Series This episode is produced in partnership with Allergy & Asthma Network, with special thanks to Genentech for sponsoring this episode.

Bytes of Health is a daily, five-minute long podcast that provides practical guidance and advice for parents of kids of all ages! It's a shame-free zone that aims to take a "byte" out of your parent worries! Be sure to subscribe, rate, and review Bytes of Health on Apple Podcasts, Spotify, Amazon, or wherever you get your podcasts. And find us on Instagram at https://www.instagram.com/bytesofhealthpod/ Interested in advertising with us? Please reach out to advertising@airwavemedia.com, with “Bytes of Health” in the subject line. PLEASE NOTE: The discussion and information provided in this podcast are for general educational, scientific, and informational purposes only and are not intended as, and should not be treated as, medical or other professional advice for any particular individual or individuals. Every person and medical issue is different, and diagnosis and treatment requires consideration of specific facts often unique to the individual. As such, the information contained in this podcast should not be used as a substitute for consultation with and/or treatment by a doctor or other medical professional. If you are experiencing any medical issue or have any medical concern, you should consult with a doctor or other medical professional. Further, due to the inherent limitations of a podcast such as this as well as ongoing scientific developments, we do not guarantee the completeness or accuracy of the information or analysis provided in this podcast, although, of course we always endeavor to provide comprehensive information and analysis. In no event may Unbiased Science or any of the participants in this podcast be held liable to the listener or anyone else for any decision allegedly made or action allegedly taken or not taken allegedly in reliance on the discussion or information in this podcast or for any damages allegedly resulting from such reliance. The information provided herein do not represent the views of our employers. Learn more about your ad choices. Visit megaphone.fm/adchoices

To have your question featured in a future video, please email: questions@drmdc.health

This episode was recorded before 31 July 2024. Professor Marcus Maurer, Dr Carolina Vera Ayala, and Associate Professor Jonny Peter discuss how new therapeutics progress through the development pipeline, noting the “huge amount of data” required on safety before a molecule enters clinical trials. They also shed light on drug repurposing and why children are a “critical group” for inclusion in trials. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Additional resources for this episode: Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria' podcast episodes! For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry. 

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from September 21-September 27, 2024.

Chronic spontaneous urticaria affects approximately 1% of the general population worldwide, impairs patients' quality of life, and is associated with multiple comorbidities. Pavel Kolkhir, MD, discusses the current evidence on the epidemiology, pathophysiology, diagnosis, and treatment of chronic spontaneous urticaria with JAMA Senior Editor Karen E. Lasser, MD, MPH. Related Content: Chronic Spontaneous Urticaria

[This episode was recorded before 31 July 2024.] "Every chronic urticaria starts as acute urticaria, but not every acute urticaria becomes chronic." Associate Professor Dr Andaç Salman and Professor Marcus Maurer discuss causes of acute urticaria, how diagnosis and management can be improved, and UCARE's research into drivers of “chronification”. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Additional resources for this episode: Acute and chronic urticaria diagnosis and management taking into account their differences; Acute urticaria – GA2LEN UCARE 2023 conference presentation and Project: CHAPEAU – GA2LEN UCARE Network Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria' podcast episodes! For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry. 

There's never been a better time to be a CSU patient, with cutting-edge therapies and revolutionary treatments just around the corner. As research accelerates, new and promising options that could significantly improve the quality of life for those living with Chronic Spontaneous Urticaria are coming to market. In this episode, Dr. Matthew Zirwas joins us to discuss the latest advancements in treating CSU, offering invaluable insights into both current and emerging treatment options. With his extensive experience and patient-centred approach, Dr. Zirwas breaks down the complexities of CSU and highlights how these new therapies can make a real difference. This podcast was made in partnership with Allergy & Asthma Network. We thank Novartis for sponsoring this podcast. What We Cover in Our Episode About Emerging Chronic Spontaneous Urticaria Treatments: How Dr. Zirwas explains CSU to his patients: Discover the patient-friendly explanations that help demystify CSU and empower patients to learn more about their disease. When to start with a biologic: Learn about the decision-making process for initiating biologic therapies like Xolair (omalizumab) and when they are most appropriate. The new medications coming to market: Get an overview of the latest advancements, including: Dupixent (dupilumab): A biologic administered via injection that targets key pathways in the inflammatory response. Remibrutinib: A BTK (Bruton tyrosine kinase) inhibitor available as a pill that blocks a crucial enzyme in mast cell activation. Barzolvolimab: A promising biologic that targets the C KIT receptor on mast cells to reduce their number. Shared decision-making with these medications: Explore strategies for choosing the most appropriate treatment in a rapidly evolving therapeutic landscape. Research into the underlying cause of CSU: What's happening on the research front to uncover the root causes of CSU. About Our Guest Dr. Matthew Zirwas, MD, is a board-certified dermatologist and a nationally recognized expert in allergy patch testing, psoriasis, and eczema. He founded the Bexley Dermatology Research Clinic, offering patients access to the latest treatment options before they are widely available. Dr. Zirwas also serves as a dermatologic advisor for several companies, including ALL Laundry Detergent and Cerave, and contributes to Women's Health Magazine. Learn more about Dr. Zirwas. More resources about chronic spontaneous urticaria:  Chronic Urticaria Management, Resources & Glossary of Terms: https://allergyasthmanetwork.org/health-a-z/chronic-urticaria/management-and-resources/ What is Chronic Urticaria: https://allergyasthmanetwork.org/health-a-z/chronic-urticaria/  More information about Omalizumab (Xolair): https://www.xolair.com/chronic-spontaneous-urticaria.html Disclaimer: This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

If you've found it frustrating that no one can tell you why you have chronic urticaria hives (including chronic spontaneous urticaria, dermatographia, and even angioedema), I feel you.Especially when IgE allergies are ruled out (testing is negative) or even avoiding what you're allergic to isn't helpful. At that point, most doctors will say that there is no answer or clear trigger to what causes urticaria, basically leaving you with an increasing number of medications that may or may not help to control your skin.To say that this leaves many like you feeling enormously helpless and hopeless is an understatement.In my clinical practice, I've worked with many cases of chronic urticaria hives around the globe, helping to troubleshoot when doctors have all but given up in seeking an answer. Some cases have dated back decades, often having been seen at some of the most prestigious health institutions only to be told that there's nothing to be done beyond antihistamines (which have their own problematic side effects) and biologics like Xolair.I love helping people stop having hives and urticaria, especially since I get to explore the complex causes of chronic urticaria, which conventional medicine often ignores or assumes is impossible. So when new research starts pointing out connections to what I have seen in practice, I must share it!If you missed my previous article on hidden causes of chronic urticaria, check it out here! This will help you see that what this new paper demonstrates is highlighting a big missing link to chronic spontaneous urticaria, hives, and other histamine-driven issues.Before we dig into gut-chronic urticaria hives connection, I highly recommend that you download my Skin Rash Root Cause Finder. This is the exact method I've used with thousands of my private clients to help them discover what's really causing their rash (and yes, this works for hives, dermatographia and angioedema issues) >> Get the easy-to-use Skin Rash Root Cause Finder.In This Episode:Chronic urticaria (hives) gut causesProblems with urticaria treatment options (even Xolair)Gut imbalances noted in chronic spontaneous urticaria (hives)What are lipopolysaccharides + short-chain fatty acids (and why are they important)?Key findings from new research on gut-skin connection (specifically for hives)Quotes“The incidence of true histamine intolerance is much lower than you're led to believe and is based on old assumptions that need a serious update.”“Nearly 50% of those living with urticaria experience depression and anxiety (especially when the flare-ups are severe).”LinksGut microbiota facilitate chronic spontaneous urticariaHealthy Skin Show ep. 261: Chronic Hives: Why Aren't They Going AwayHealthy Skin Show ep. 265: Problem with Antihistamines That No One Tells You w/ Dr. Chris Thompson, MDHealthy Skin Show ep. 317: Itchy, Painful Rash From Thyroid Disease: Your Guide to Stopping ItHealthy Skin Show ep. 188: Histamine Intolerance + Skin Rashes (PART 1)